Progenics Pharmaceuticals Announces a Changing of the Guard on Its Board Of
-Michael Kishbauch, former CEO of Achillion, joins Board
-Stephen Goff retires from Board following 20 years of service
TARRYTOWN, N.Y., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) has announced that Michael D. Kishbauch, an experienced and
innovative leader in the healthcare industry, has been elected to its Board of
Directors. Stephen P. Goff, Ph.D., who has served on the Board since 1993, has
retired. Both are effective today. Mr. Kishbauch has held senior management
positions in the life sciences industry for over 28 years, most recently as
President and CEO of Achillion Pharmaceuticals.
"Our newest Board member brings a wealth of experience, expertise and
enthusiasm to our team," said Peter Crowley, Chairman of the Board of
"The Board at Progenics is instrumental in providing the vision and support
needed to further our mission to become a pre-eminent oncology company. We are
honored to welcome Michael to our Board as we work to address the unmet
medical needs of cancer patients and their families," said Mark R. Baker,
Chief Executive Officer.
Mr. Kishbauch has extensive operational, strategic, product planning,
promotion, sales, marketing and product launch experience. Prior to his work
at Achillion, Michael founded and served as President and Chief Executive
Officer of OraPharma, Inc., which was a publicly traded, commercial-stage
pharmaceutical company focused on oral health care. OraPharma was acquired by
Johnson & Johnson. Michael previously held senior management positions with
MedImmune, Inc.; has held board positions with several other life sciences
companies; and continues to serve on Achillion's Board. He holds an M.B.A.
from the Wharton School of the University of Pennsylvania and a B.A. in
biology from Wesleyan University.
"I am pleased for the opportunity to help guide Progenics, and grateful to
play a role in fundamentally changing the landscape for patients suffering
from prostate and other cancers," said Mr. Kishbauch. "My experience in the
healthcare sector helps me to appreciate the value an organization like
Progenics brings in advancing innovative, yet practical, approaches to
diagnosing and treating prostate and other cancers."
Dr. Goff is stepping down from the Progenics Board after 20 years of service.
"Steve Goff has inspired generations of Progenics scientists throughout his
tenure," said Mark Baker. "We will miss his wisdom and guidance."
Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development. Progenics' first-in-class PSMA targeted
technology platform includes an antibody drug conjugate therapeutic and a
small molecule targeted imaging agent, both in Phase 2 clinical trials. Among
other assets in its pipeline of targeted radiotherapy and molecular imaging
compounds is Azedra^TM, an ultra-orphan radiotherapy candidate also in phase 2
under an SPA.Progenics' first commercial product, Relistor^®
(methylnaltrexone bromide) for opioid-induced constipation, is partnered with
and marketed by Salix Pharmaceuticals, Inc.Ono Pharmaceutical Co. is
developing Relistor in Japan. For additional information, please visit
This release may contain projections and other forward-looking statements
regarding future events. Such statements are predictions only, and are subject
to risks and uncertainties that could cause actual events or results to differ
materially. These risks and uncertainties include, among others, the cost,
timing and results of clinical trials and other development activities; the
unpredictability of the duration and results of regulatory review of New Drug
Applications and Investigational NDAs; market acceptance for approved
products; generic and other competition; the possible impairment of, inability
to obtain and costs of obtaining intellectual property rights; and possible
safety or efficacy concerns, general business, financial and accounting
matters, litigation and other risks. More information concerning Progenics and
such risks and uncertainties is available on its website, and in its press
releases and reports it files with the U.S. Securities and Exchange
Commission. Progenics is providing the information in this release as of its
date and does not undertake any obligation to update or revise it, whether as
a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available
in press releases or other public announcements and public filings made after
CONTACT: Contacts for Progenics Pharmaceuticals:
Director, Corporate Development
Press spacebar to pause and continue. Press esc to stop.